Evidence map›Paper›PMID 40148307›Full record

SynthesisAnti-cancer agents in medicinal chemistry2025

Clinical Efficacy and Safety of Pembrolizumab Therapy for B-cell Lymphoma: A Systematic Review and Meta-analysis.

Behrouz Robat-Jazi, Mohammad Amin Habibi, Negar Nejati, Ali Zand, Mohsen Dashti, Parsa Lorestani, Mahsa Ahmadpour, Negar Dokhani, Aida Rezaei Nejad, Shaghayegh Karami and 3 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Anti-cancer agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Behrouz Robat-JaziResearch Center for Chronic Inflammatory Diseases, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Amin HabibiClinical Research Development Center, Qom University of Medical Sciences, Qom, Iran.
Negar NejatiPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ali ZandSchool of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Mohsen DashtiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Parsa LorestaniStudents Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mahsa AhmadpourShahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Negar DokhaniCardio-Oncology Research Center, Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Aida Rezaei NejadStem Cell and Regenerative Medical Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
Shaghayegh KaramiSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Erfan AlinejadDepartment of Medicine, Babol University of Medical Sciences, Babol, Iran.
Amir H MalekijooDepartment of Computer Engineering, Semnan University, Semnan, Iran.
Farhad Jadidi-NiaraghImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

Tabriz University of Medical Sciences 75378
6 · The paper itself

Abstract

backgroundCertain types of non-Hodgkin lymphoma, such as Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL), often necessitate multiple treatment approaches. One promising avenue is immune checkpoint inhibition, specifically targeting the programmed cell death protein 1 (PD-1). Pembrolizumab, an immunotherapy medication, acts by inhibiting the PD-1 pathway and has gained approval from the United States Food and Drug Administration (FDA) for treating various cancers, including melanoma, Hodgkin lymphoma, lung cancer, and endometrial cancer. This meta-analysis aims to assess the impact of pembrolizumab on patient outcomes and survival in the context of B-cell lymphoma.

methodsThis study adhered to The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Two independent reviewers conducted a thorough search of electronic databases up to September 28, 2023. We included studies that investigated the effects of pembrolizumab treatment on patient outcomes and survival in individuals diagnosed with B-cell lymphoma. All statistical analysis was performed by STATA V.17.

resultsOur meta-analysis encompassed 13 eligible clinical trials involving 426 B-cell lymphoma patients. The study findings revealed a Disease Control Rate (DCR) of 63%, Overall Response Rate (ORR) of 42%, Complete Response Rate (CRR) of 23%, and 1-year Overall Survival Rate (OSR) of 64%. Notably, 65% of patients experienced Treatment-Related Adverse Events (TRAEs) of any grade, with 39% encountering grade ≥ 3 TRAEs. The most prevalent grade ≥ 3 TRAEs included anemia, neutropenia, thrombocytopenia, and lymphopenia.

conclusionThe utilization of pembrolizumab, both as a monotherapy and in combination with other drugs, presented encouraging outcomes in patients with B-cell lymphoma.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalLymphoma, B-CellHumansAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabB-cell lymphomachemoimmunotherapyDLBCL.immunotherapyNon-hodgkin lymphomapembrolizumab

Identifiers

PMID40148307

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.